https://www.prnewswire.co.uk/news-releases/jazz-pharmaceuticals-presents-data-for-the-phase-3-tones-2-study-of-jzp-110-in-patients-with-excessive-626841251.html
Jazz Pharmaceuticals Presents Data for the Phase 3 TONES 2 Study of JZP-110 in Patients with...
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today presented the positive efficacy results from its global multicenter study of JZP-110 in adult...